KEYNOTE-F25, NCT05761223: A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 |
|
|
| Recruiting | 1/2 | 151 | US | Phase Ia dose-escalation part of FB849 Monotherapy, FB849, Phase Ib dose-expansion of FB849 monotherapy, Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab, KEYTRUDA®, Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer), Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer), Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer) | 1ST Biotherapeutics, Inc., Merck Sharp & Dohme LLC | Advanced Solid Tumor | 06/26 | 10/26 | | |
